Chlamydia Infection Diagnostics Market to be Dominated by Nucleic Acid Amplification Test (NAAT) Through 2028
Rising Prevalence of Chlamydia Infections and increasing awareness regarding women’s health are driving Global Chlamydia Infection Diagnostics Market in the forecast period 2024-2028.
According to TechSci Research report, “Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028”, Global Chlamydia infection diagnostics market stood at USD 678.56 million in 2022 and is anticipated to grow at a CAGR of 6.06% through 2028. The market is driven by the increasing prevalence of Chlamydia infections globally. According to the World Health Organization (WHO), Chlamydia is one of the most common bacterial STIs worldwide, affecting millions of people each year. This alarming rise in infection rates has emphasized the need for robust diagnostic tools to identify and manage Chlamydia infections promptly. Awareness campaigns and proactive screening programs have played a pivotal role in driving the demand for Chlamydia infection diagnostics. Governments, healthcare organizations, and NGOs are working collectively to raise awareness about the risks associated with untreated Chlamydia infections and the importance of early detection. These efforts have led to increased testing rates, thus boosting the market for Chlamydia diagnostics.
The potential for Chlamydia transmission from infected individuals to their sexual partners is a significant concern. Timely diagnosis and treatment not only benefit the individual's health but also contribute to reducing the overall transmission rates of the infection. Governments and healthcare organizations worldwide are recognizing the importance of diagnostics in disease control and prevention, thereby fostering market growth. Further, regulatory bodies play a crucial role in shaping the diagnostics market landscape. Favorable regulatory environments that promote the development and approval of accurate diagnostic tests have provided a conducive ecosystem for Chlamydia infection diagnostics manufacturers. Streamlined regulatory pathways have facilitated the introduction of innovative diagnostic solutions into the market.
However, Privacy concerns often discourage individuals from seeking testing for STIs, including chlamydia. The fear of having their personal information exposed can be a deterrent. Addressing these concerns through anonymous testing options and effective communication about data protection is vital to encourage more people to get tested, which may hamper the growth of the market in the projected period.
Global Chlamydia Infection Diagnostics is segmented based on Test Type, Type of Infection and End User.
Based on Test Type, the market is divided into Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other. The Nucleic Acid Amplification Test (NAAT) segment is expected to witness a rise over the forecast period. This is attributed to the fact that NAAT is used in genetic testing to identify mutations associated with genetic disorders, prenatal screening, and paternity testing. This has led to more accurate and reliable genetic information.
Based on Type of Infection, the market is divided into Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection. The Genital Chlamydia Infection segment is expected to witness a rise over the forecast period. This is attributed to the fact that Genital chlamydia infection is a common STI with potentially serious consequences if left untreated.
Based on End User, the market is divided into Hospitals, Specialty Clinics, Diagnostics Centre. The Hospitals segment is expected to witness a rise over the forecast period. This is attributed to the rising urbanization and infrastructural development all over the world.
Major companies operating in Global Chlamydia Infection
Diagnostics marketare:
- Abbott
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc
- Quidel Corporation
- DiaSorin SpA
- AstraZeneca
- Teva Pharmaceutical Industries
Limited
Customers can also request for 10% free customization on this report.
" North America's domination in Chlamydia infection diagnostics reflects its commitment to advancing healthcare through technological innovation, research, and proactive public health initiatives. The region's ability to combine cutting-edge diagnostic methods with accessible healthcare infrastructure has led to early detection, timely treatment, and a reduced burden of chlamydia infection. As the region continues to invest in healthcare advancements and collaborative research, its leadership in Chlamydia infection diagnostics is likely to persist, making a lasting impact on global health and are creating favorable conditions to boost the global demand for Chlamydia Infection Diagnostics till 2028.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“Chlamydia Infection Diagnostics Market, By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other), By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection), By End User (Hospitals, Specialty Clinics, Diagnostics Centre), By Region, By Competition Forecast & Opportunities, 2018-2028F., has evaluated the future growth potential of global Chlamydia Infection Diagnostics and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Chlamydia Infection Diagnostics market.”
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com